Barclays’s Tobira Therapeutics, Inc. Common Stock TBRA Stock Holding History

Barclays’s Portfolio TBRA Stock Details TBRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-56	Closed	-$2K	–	7091
2016 Q3	$2K	Buy	+56	New	+$625	﹤0.01%	6343
2015 Q4	–	Sell	-12	Closed	–	–	7078
2015 Q3	$0	Sell	12 -35	-74%	-$491	﹤0.01%	7273
2015 Q2	$1K	Sell	47 -4	-8%	-$58	﹤0.01%	6967
2015 Q1	$0	Sell	51 -47	-48%	-$505	﹤0.01%	7400
2014 Q4	$0	Sell	98 -245	-71%	-$2.11K	﹤0.01%	7827
2014 Q3	$3K	Buy	343 +305	+803%	+$6.03K	﹤0.01%	7367
2014 Q2	$2K	Sell	38 -6	-14%	-$365	﹤0.01%	7460
2014 Q1	$5K	Buy	+44	New	+$3.09K	﹤0.01%	7234

Barclays's TBRA Position: Q4 2016 in Review

Barclays sold out of Tobira Therapeutics, Inc. Common Stock (TBRA) in Q4 2016, closing a stake of 56 shares — an estimated $2K sold.

Barclays first reported a position in TBRA in Q1 2014 and held it in 8 quarters. The position peaked at $5K in Q1 2014. 0 funds tracked by Wall St. Rank hold TBRA as of Q4 2016.

Barclays reported no remaining Tobira Therapeutics, Inc. Common Stock position as of Q4 2016 after selling out during the quarter.
Barclays sold 56 Tobira Therapeutics, Inc. Common Stock shares in Q4 2016, an estimated $2K.
Barclays first reported a position in Tobira Therapeutics, Inc. Common Stock in Q1 2014 and held it in 8 quarters.
Barclays's Tobira Therapeutics, Inc. Common Stock position peaked at $5K in Q1 2014.
0 funds tracked by Wall St. Rank held Tobira Therapeutics, Inc. Common Stock as of Q4 2016.

Based on Barclays's 13F filing for Q4 2016, filed 14 Feb 2017.